Cargando…

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

BACKGROUND: Dose banding is a recently suggested dosing method that uses predefined ranges (bands) of body surface area (BSA) to calculate each patient’s dose by using a single BSA-value per band. Thus, drugs with sufficient long-term stability can be prepared in advance. The main advantages of dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatelut, E, White-Koning, M L, Mathijssen, R HJ, Puisset, F, Baker, S D, Sparreboom, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461153/ https://www.ncbi.nlm.nih.gov/pubmed/22929884 http://dx.doi.org/10.1038/bjc.2012.357

Ejemplares similares

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
por: Janssen, A, et al.
Publicado: (2017)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
por: Viala, Marie, et al.
Publicado: (2018)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
por: Smith, N F, et al.
Publicado: (2008)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

Overestimation of carboplatin doses is avoided by radionuclide GFR measurement
por: Craig, A J, et al.
Publicado: (2012)

Embracing model-based designs for dose-finding trials
por: Love, Sharon B, et al.
Publicado: (2017)

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway
por: Ghebeh, H, et al.
Publicado: (2014)

Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells
por: González, A, et al.
Publicado: (2007)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
por: Zucali, P A, et al.
Publicado: (2013)

Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model
por: Thies, A, et al.
Publicado: (2008)

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation
por: Feng, Hao, et al.
Publicado: (2018)

Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid
por: Niedre, M J, et al.
Publicado: (2005)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy
por: Xue, H, et al.
Publicado: (2009)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013)

Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts
por: Eicher, C, et al.
Publicado: (2013)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
por: Vass, S O, et al.
Publicado: (2009)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
por: Horiguchi, A, et al.
Publicado: (2010)

Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
por: Bruynzeel, A M E, et al.
Publicado: (2007)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n0c6006kq8bulat2qmfqe24jgs